# A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

> **NCT07711418** · PHASE3 · RECRUITING · sponsor: **Nektar Therapeutics** · enrollment: 510 (estimated)

## Conditions studied

- Moderate-to-Severe Atopic Dermatitis

## Interventions

- **DRUG:** Rezpegaldesleukin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07711418
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-07
- **Primary completion:** 2028-06
- **Final completion:** 2029-01
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2026-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711418, "A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07711418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*